» Articles » PMID: 15194426

Retinoic Acid Regulates Cell Cycle Progression and Cell Differentiation in Human Monocytic THP-1 Cells

Overview
Journal Exp Cell Res
Specialty Cell Biology
Date 2004 Jun 15
PMID 15194426
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

All-trans-retinoic acid (RA), a natural metabolite of retinol, carries out most of the biological activities of vitamin A and is required for normal growth, cell differentiation, and immune functions. In the present studies, THP-1 human monocytes were used to investigate the mechanisms by which RA may regulate progression through the G1/S phase of the cell cycle. Physiological concentrations of all-trans-RA reduced the levels of cyclin E mRNA by 6 h and reduced cyclin E protein in a dose- and time-dependent manner. Similar reductions were observed for the retinoic acid receptor RARalpha and RXRalpha proteins. Concomitantly, RA increased the level of the cyclin-dependent kinase inhibitor p27 (Kip-1). The levels of retinoblastoma mRNA and protein (pRb) were also increased, while the proportion of hyperphosphorylated (phosphoserine 807/811) pRb was markedly reduced. Overall, RA increased the functionality of pRb as an inhibitor of cell cycle progression. Furthermore, RA reduced the binding activity of the transcription factor E2F to its core DNA element. Retinoic acid-induced changes in cell cycle-related proteins occurred in 4-6 h, including reduced cyclin E expression in bromodeoxyuridine (BrdU)-labeled cells, before the onset of cell differentiation as indicated by an increase in the percentage of G1 phase cells and a reduction in S phase cells at 24 h. The expression of CD11b, a cell surface marker of macrophage-like differentiation was increased by RA, as was phagocytic activity. The multiple effects of RA on cell cycle progression may help to explain its well-documented ability to induce the differentiation of THP-1 cells, and thereby to enhance macrophage-like immune functions.

Citing Articles

The standardization and efficacy of fermented (L.) in combination with enrofloxacin against artificially induced pneumonic pasteurellosis in rat models.

Prakoso Y, Susilo A, Widyarini S Open Vet J. 2025; 14(12):3404-3416.

PMID: 39927353 PMC: 11799618. DOI: 10.5455/OVJ.2024.v14.i12.25.


Alcohol Consumption and Breast and Ovarian Cancer Development: Molecular Pathways and Mechanisms.

Fanfarillo F, Caronti B, Lucarelli M, Francati S, Tarani L, Ceccanti M Curr Issues Mol Biol. 2024; 46(12):14438-14452.

PMID: 39727994 PMC: 11674816. DOI: 10.3390/cimb46120866.


Immune regulation is more effective in the U937 inflammation model with mesenchymal stem cell extracellular vesicles stimulated by pro-inflammatory cytokines.

Ozturk C, Halbutogullari Z Cent Eur J Immunol. 2024; 49(3):282-299.

PMID: 39720277 PMC: 11664804. DOI: 10.5114/ceji.2024.143726.


In silico analysis of potential inhibitors for breast cancer targeting 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) catalyses.

Islam M, Tayyeb J, Paul H, Islam M, Oduselu G, Bayil I J Cell Mol Med. 2024; 28(15):e18584.

PMID: 39135338 PMC: 11319393. DOI: 10.1111/jcmm.18584.


Butyrate and tributyrin reduce LPS-induced inflammatory cytokine production from human visceral fat.

Rafiei H, Yeung M, Kowalski S, Li M, Harris D, Chang J Int J Obes (Lond). 2024; 48(11):1559-1567.

PMID: 38987636 DOI: 10.1038/s41366-024-01581-9.


References
1.
Knudsen E, Wang J . Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem. 1996; 271(14):8313-20. DOI: 10.1074/jbc.271.14.8313. View

2.
Kitagawa M, Higashi H, Jung H, Suzuki-Takahashi I, Ikeda M, Tamai K . The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 1996; 15(24):7060-9. PMC: 452531. View

3.
Lippman S, Lotan R, Schleuniger U . Retinoid-interferon therapy of solid tumors. Int J Cancer. 1997; 70(4):481-3. DOI: 10.1002/(sici)1097-0215(19970207)70:4<481::aid-ijc20>3.0.co;2-h. View

4.
Harper J, Goodrich D . Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997; 8(2):287-301. PMC: 276080. DOI: 10.1091/mbc.8.2.287. View

5.
Chen G, Shi X, Tang W, Xiong S, Zhu J, Cai X . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997; 89(9):3345-53. View